1. National R&D Oncology Consortium PI: J. Tímár MD PhD National Institute of Oncology Rath Gy 7-9, Budapest,H-1122 Hungary

2. Cancer morbidity and mortality’1999, Hungary femalemale MT (15000) MB MT (19000) MB

3. National Oncology R&D Conzorcium (Hungary) National Institute of Neurosurgery National Institute of Pulmonology National Institute of Epidemiology Department of Pediatrics, Debrecen U. Department of Immunology and Biotechnology, Pécs University 1st Institute of Pathology & Experimental Cancer Research, Semmelweis University, Budapest National Institute of Neurosurgery National Institute of Pulmonology National Institute of Epidemiology Department of Pediatrics, Debrecen U. Department of Immunology and Biotechnology, Pécs University 1st Institute of Pathology & Experimental Cancer Research, Semmelweis University, Budapest Department of Oncotherapy, Szeged University Institute of Biotechnology, Bay Z. Fundation, Szeged National Institute of Rabiobiology AstraZeneca Hungary Aventis Pharma Hungary Béres Co. Hungary Byk-Gulden Janssen-Cilag, Johnson and Johnson Pannonpark Ltd Pharmacia Hungary Bristol-Myers-Squibb Hungary Department of Oncotherapy, Szeged University Institute of Biotechnology, Bay Z. Fundation, Szeged National Institute of Rabiobiology AstraZeneca Hungary Aventis Pharma Hungary Béres Co. Hungary Byk-Gulden Janssen-Cilag, Johnson and Johnson Pannonpark Ltd Pharmacia Hungary Bristol-Myers-Squibb Hungary National institute of Oncology

4. Cancer types to be investigated Breast ca. Lung ca. Colorectal ca. Head and neck ca. Cervical ca. Ovarian ca. Malignant melanoma Soft tissue sarcoma Pediatric cancers: acute leukemia neuroblastoma nephroblastoma glioblastoma Breast ca. Lung ca. Colorectal ca. Head and neck ca. Cervical ca. Ovarian ca. Malignant melanoma Soft tissue sarcoma Pediatric cancers: acute leukemia neuroblastoma nephroblastoma glioblastoma

5. Methodology Laser-microdissection Global genome analysis DNA microarry design, production real time quantitatív PCR antibody design and production protein-chip technology in situ hibridization Laser-microdissection Global genome analysis DNA microarry design, production real time quantitatív PCR antibody design and production protein-chip technology in situ hibridization

6. Laser-microdissection DNS protein RNS

7. Breast cancer T V N GAPDH MAM HER-2 TOPT II Mutational analysis

8. 10x 20x 40x 80x 160x 2 kópia 1 kópia Quantitative PCR

9. Confocal Laser scanning microscopy

10. Screening and prevention Susceptibility: drug metabolizing enzim-polymorphism Familiar breast, ovarian and colorectal cancer screening Genetical predisposition Neuroblastoma Susceptibility: drug metabolizing enzim-polymorphism Familiar breast, ovarian and colorectal cancer screening Genetical predisposition Neuroblastoma

11. Diagnostics Molecular diagnostics soft tissue tumors Molecular staging colorectal-, breast-, head and neck, ALL, NBL Prognostic pathology colorectal-, breast-, lung-,head and neck, melanoma Sensitivity to therapy: drug metabolizing enzime polymorphism drug-target identification Molecular diagnostics soft tissue tumors Molecular staging colorectal-, breast-, head and neck, ALL, NBL Prognostic pathology colorectal-, breast-, lung-,head and neck, melanoma Sensitivity to therapy: drug metabolizing enzime polymorphism drug-target identification

12. Novel therapeutic modalities Breast cancer: Chemoprevention, New taxanes combination of taxanes and Herceptin Melanoma: Fragmin (lmw heparin) Cervical ca., rectal ca: rhErythropoetin Glioblastoma: gene therapy Breast cancer: Chemoprevention, New taxanes combination of taxanes and Herceptin Melanoma: Fragmin (lmw heparin) Cervical ca., rectal ca: rhErythropoetin Glioblastoma: gene therapy

13. Biotech products New method for blood detection in the stool WT1 oncogene probes, antibodies “Designer” oligo-chips for differential diagnosis of soft tissue tumors drug targets in breast-, head and neck cancers Gene-map of tumor progression drig metabolizing enzime polymorphism Design of protein chips for tumor progression cytokine-producing vestor systems geneticaly engenered human glioblastoma cell lines New method for blood detection in the stool WT1 oncogene probes, antibodies “Designer” oligo-chips for differential diagnosis of soft tissue tumors drug targets in breast-, head and neck cancers Gene-map of tumor progression drig metabolizing enzime polymorphism Design of protein chips for tumor progression cytokine-producing vestor systems geneticaly engenered human glioblastoma cell lines

14. 1.Mol - epidemiol OTFH ANTSZ SZBK 2.Screening and prognosis of colorectal cancer 2.Screening and prognosis of colorectal cancer 3.Moldiagnostics3.Moldiagnostics 4. Mol.diag. therapy of breastcc 4. Mol.diag. therapy of breastcc 5.Mol.epidemiol. Diag. of head and neck cancer 5.Mol.epidemiol. Diag. of head and neck cancer 9.Gene therapy of brain tumors 9.Gene therapy of brain tumors 6. Pediatric oncology 7.TumorProgression7.TumorProgression 8.Molecularpharmacology8.Molecularpharmacology BYK SZBK OKTPI SZE-OTK SZBK AstraZenecaAventisPharmavitBMS BYK DE-GYK SZBK PTE-IBISZBK PharmaciaJansen-Cilag SE-1PKRKISZBK Pharmacia BayZAOSSKI OIsTI Béres Rt Béres Rt. J. Tímár PI